PHAKIC IOL IMPLANTATION (ICL) TO TREAT AMETROPIA IN EYES WITH STABILIZED KERATOCONUS (KCN), PREVIOUSLY TREATED WITH THE ATHENS PROTOCOL CXL (AP CXL)
Published 2025 - 29th ESCRS Winter Meeting
Reference: PO043 | Type: Free Paper | DOI: 10.82333/crmp-jf40
Authors: Vasiliki Moustou* 1 , Anastasios John Kanellopoulos 2 , Alexandros Kanellopoulos 1 , Despoina Karadimou 1
1Ophthalmology,Laservision Ambulatory Eye Surgery Unit,Athens,Greece, 2Ophthalmology,Laservision Ambulatory Eye Surgery Unit,Athens,Greece;Ophthalmology,NYU Med School,New York,United States
Purpose
To evaluate the safety and efficacy of refractive correction with ICL implantation in eyes which have undergone AP CXL for KCN.
Setting
The Laservision.gr Clinical and Research Institute, Athens, Greece
Methods
An observational Consecutive Case Series; 15 eyes previously treated with AP CXL for KCN were treated with ICL implantation for refractive error correction, as the residual stromal thickness was prohibitive of a cornea laser ablation. In all cases a toric phakic IOL (EVO Plus ICL, STAAR, Nidau, Switzerland) were used.UDVA, CDVA, refraction and ICL position as measured by anterior segment OCT and ICL placement were evaluated up to the 6 month follow-up.
Results
In all cases an ICL was uneventfully implanted and achieved good clinical position. When comparing pre-ICL to 6 month post: UDVA changed from 20/80 to 20/30, CDVA changed from 20/40 to 20/25, the refractive error in spherical equivalent from -4.5 D (range -2.5 D to -18 D) to -0.75 D (+0.50 to -1.75), refractive cylinder from -2.75 D (range -1 to -4.25 D).
Conclusion
We report safe and efficient outcomes when using the ICL to address significant ametropia in keratoconic eyes previously treated with AP CXL.